Sunday 11 October 2026
Export all EQ data to Excel Powerpack
Equillium, Inc.
Equillium, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $41.1 million, up 13.9% from fiscal 2023. In the quarter to June 2026, revenue fell 52.3%, EPS grew 75.0% and free cash flow fell 38.7%, each against the same quarter a year earlier. Dividend growth for three consecutive years, revenue growth for three.
1.41
0.03
−2.08%
Follow EQ
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | 5.50 | 2.56 | 2.20 | 3.66 | 0.79 | 0.45 | 0.56 | 0.27 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | 19.69 | 13.32 | 27.05 | 11.33 | 4.38 | 1.35 | 3.25 | 2.35 | |||||
| People | |||||||||||||||
| People | Employees | — | 7 | 11 | 16 | 31 | 45 | 36 | 44 | 35 | 14 | ||||
| Revenue/emp, $m | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.44 | 0.82 | 1.17 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | 16 | 36 | 41 | — | ||||
| Gross margin, % | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 100.00 | 100.00 | 100.00 | — | |||||
| EBT | — | (2) | (13) | (26) | (30) | (39) | (62) | (13) | (8) | (22) | |||||
| EBT margin, % | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (396.14) | (35.35) | (18.75) | 0.00 | |||||
| Net income | — | (2) | (13) | (26) | (30) | (39) | (62) | (13) | (8) | (22) | |||||
| Depreciation | — | 0 | 0 | 0 | 0 | 1 | 0 | (1) | (1) | 0 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.47 | 1.04 | 1.16 | 0.00 | ||||
| Earnings | — | (0.22) | (1.09) | (1.47) | (1.46) | (1.36) | (1.85) | (0.38) | (0.23) | (0.39) | |||||
| Cash flow | — | (0.07) | (0.62) | (1.32) | (1.21) | (1.11) | (0.26) | (0.63) | (0.54) | (0.40) | |||||
| Capex | — | 0.00 | 0.00 | 0.00 | (0.01) | 0.00 | (0.01) | 0.00 | 0.00 | 0.00 | |||||
| Free cash flow | — | (0.07) | (0.62) | (1.32) | (1.22) | (1.12) | (0.27) | (0.63) | (0.54) | (0.40) | |||||
| Book value | — | (0.22) | 5.33 | 2.41 | 3.43 | 2.31 | 0.95 | 0.65 | 0.54 | 0.50 | |||||
| Shares, m | — | 10 | 12 | 17 | 20 | 29 | 34 | 35 | 35 | 57 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | — | ||||
| P/S | — | — | — | — | — | — | 0.00 | 0.70 | 0.65 | — | |||||
| P/B | — | — | — | — | — | — | 1.12 | 1.12 | 1.39 | — | |||||
| EV/Sales | — | — | — | — | — | — | 0.00 | (0.22) | 0.28 | — | |||||
| EV/FCF | — | — | — | — | — | — | 2.92 | 0.36 | (0.60) | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | (1) | (8) | (23) | (25) | (32) | (9) | (22) | (19) | (23) | ||||
| Capex | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
| Free cash flow | — | (1) | (8) | (23) | (25) | (32) | (9) | (22) | (19) | (23) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | 7 | 65 | 52 | 78 | 74 | 45 | 22 | 19 | 28 | ||||
| Total debt | — | 8 | — | 10 | 10 | 10 | 9 | — | — | — | |||||
| Net debt | — | 1 | (66) | (43) | (72) | (71) | (62) | (41) | (23) | (30) | |||||
| Shareholders’ equity | — | (2) | 65 | 42 | 70 | 67 | 32 | 23 | 19 | 29 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | (6.09) | (35.66) | (41.73) | (42.30) | (45.72) | (76.21) | (20.68) | (21.19) | (77.92) | ||||
| ROIC | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| ROE | — | (7.22) | (42.28) | (47.95) | (53.38) | (57.28) | (126.83) | (48.92) | (38.75) | (93.99) | |||||
Negative figures in brackets.
Fiscal years to Dec 2024 · latest quarter Dec 2024
Charts ten years each
Equillium, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| OKUR OnKure Therapeutics, Inc. | $93.2M | — (loss-making) | — | — | n/m | +22.05% (above 0%: growing) | 0.00% | 0.00% | Compare |
| ATRA Atara Biotherapeutics, Inc. | $92.6M | — (loss-making) | — (loss-making) | −96.42% (below 0%: shrinking) | n/m | +52.10% (above 0%: growing) | 69.68% | (749.21%) | Compare |
| VXRT VAXART, INC. | $92.4M | 2.8× | 2.1× | −31.58% (below 0%: shrinking) | n/m | +117.38% (above 0%: growing) | 100.00% | (48.45%) | Compare |
| EQ Equillium, Inc. | $91.3M | — (loss-making) | — (loss-making) | −52.32% (below 0%: shrinking) | n/m | −38.67% (below 0%: shrinking) | 100.00% | 0.00% | |
| CLLS Cellectis S.A. | $90.4M | — (loss-making) | — | −62.05% (below 0%: shrinking) | n/m | −36.95% (below 0%: shrinking) | 100.00% | (340.69%) | Compare |
| RLYB Rallybio Corporation | $90.2M | 2.1× | — (loss-making) | 0.00% | n/m | +648.02% (above 0%: growing) | 100.00% | 0.00% | Compare |
| NMRA Neumora Therapeutics, Inc. | $90.2M | — (loss-making) | — | — | n/m | +24.45% (above 0%: growing) | 0.00% | 0.00% | Compare |
| MIST Milestone Pharmaceuticals Inc. | $88.7M | — (loss-making) | — (loss-making) | −62.73% (below 0%: shrinking) | n/m | −80.81% (below 0%: shrinking) | 94.28% | (4,584.97%) | Compare |
| ICCC ImmuCell Corporation | $88.6M | 114× | — (loss-making) | +11.50% (above 0%: growing) | +233.33% (above 0%: growing) | +54.86% (above 0%: growing) | 33.92% | 26.93% | Compare |
| Median of peers | $90.3M | 2.8× | — | −46.82% | — | +38.28% | 81.98% | (24.22%) |
Equillium, Inc. (EQ) key facts
- Strength: Equillium, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $41.1 million, up 13.9% from fiscal 2023.
- Equillium, Inc. (EQ) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 9, 2026, EQ traded at $1.41, a market capitalization of $91.3 million.
- Return on equity was −94.0% and debt-to-equity 0.00.
- Its Piotroski F-score is 3 out of 9 and its Altman Z-score is −6.75 (distress zone) for fiscal 2024.